StockMirror — Stock Screener

FORTIS Q2 FY27 Results & Earnings Analysis

Sentiment: Neutral (Confidence: medium)

Earnings Summary

Fortis Healthcare reported a strong quarter with consolidated revenue growing 17.3% YoY to INR 2,735 crores and EBITDA margin expanding by 30 bps to 24.2%, led by its hospital business. The company is on an aggressive expansion path, planning to add ~2,200 beds over the next 3-5 years with a CAPEX of INR 3,500 crore. However, the outlook is tempered by significant regulatory headwinds from new drug price caps, which have led management to project flat margins for FY'27 and withhold guidance for FY'28. While the long-term margin target of 25% for FY'29 is maintained, it is contingent on mitigating these regulatory impacts. The diagnostics business showed volume growth but at a slower pace than peers, with management targeting mid-teens growth in the medium term. The company's balance sheet remains healthy with a net debt-to-EBITDA of 0.87x, and it is well-positioned for future growth, supported by internal accruals and potential capital from its parent, IHH .

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

The company is actively pursuing growth through significant bed capacity expansion (~2,200 beds) and acquisitions . At the same time, management is focused on profitability, as evidenced by their attempts to improve margins and their explicit longer-term FY'29 margin target of 25%, even as they navi

About Fortis Healthcare Limited

Fortis Healthcare Limited (FORTIS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More